CIK 0001061983
- Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 943291317
- Phone
- +1 650-624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $13,320,469
- in 18 filings, $12.5M under 10b5-1 plans
Net −$13,320,469. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Blum Robert I −$9.7M President & CEO sold 34% of stake
- Malik Fady Ibraham −$1.3M EVP Research & Development sold 12% of stake
- Hessekiel Jeffrey −$795K Chief Legal & Admin Officer sold 14% of stake
- Callos Andrew −$702K EVP, Chief Commercial Officer sold 15% of stake
- PARSHALL B LYNNE −$631K Director sold 63% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-06 | Malik Fady Ibraham EVP Research & Development | Shares withheld for taxes | −8,109 | $66.88 | $542K | 121,234 |
| 2024-03-06 | Blum Robert I President & CEO | Shares withheld for taxes | −16,725 | $66.88 | $1.1M | 399,731 |
| 2024-03-06 | Callos Andrew EVP, Chief Commercial Officer | Shares withheld for taxes | −5,103 | $66.88 | $341K | 46,946 |
| 2024-03-05 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −4,000 | $67.53 | $270K | 138,973 |
| 2024-03-05 | Malik Fady Ibraham EVP Research & Development | Exercise or conversion 10b5-1 | +28,604 | $6.67 | $191K | 167,577 |
| 2024-03-05 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −28,604 | $67.56 | $1.9M | 138,973 |
| 2024-03-05 | Malik Fady Ibraham EVP Research & Development | Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −28,604 | 28,605 | ||
| 2024-03-04 | Wong Robert VP, Chief Accounting Officer | Shares withheld for taxes | −1,783 | $67.68 | $121K | 26,442 |
| 2024-03-04 | Malik Fady Ibraham EVP Research & Development | Shares withheld for taxes | −9,630 | $67.68 | $652K | 133,343 |
| 2024-03-04 | Blum Robert I President & CEO | Shares withheld for taxes | −25,341 | $67.68 | $1.7M | 416,456 |
| 2024-03-04 | Callos Andrew EVP, Chief Commercial Officer | Shares withheld for taxes | −2,202 | $67.68 | $149K | 52,049 |
| 2024-02-14 | HENDERSON JOHN T Director | Exercise or conversion 10b5-1 | +5,000 | $4.44 | $22K | 47,632 |
| 2024-02-14 | HENDERSON JOHN T Director | Sale 10b5-1 | −5,000 | $76.48 | $382K | 42,632 |
| 2024-02-14 | HENDERSON JOHN T Director | Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,000 | 0 | ||
| 2024-02-13 | Blum Robert I President & CEO | Exercise or conversion 10b5-1 | +12,500 | $6.67 | $83K | 454,297 |
| 2024-02-13 | Blum Robert I President & CEO | Sale 10b5-1 | −12,500 | $76.85 | $961K | 441,797 |
| 2024-02-13 | Blum Robert I President & CEO | Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −12,500 | 118,494 | ||
| 2024-02-06 | Malik Fady Ibraham EVP Research & Development | Exercise or conversion 10b5-1 | +28,605 | $6.67 | $191K | 175,578 |
| 2024-02-06 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −28,605 | $79.30 | $2.3M | 146,973 |
| 2024-02-06 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −4,000 | $79.28 | $317K | 142,973 |
Page 35 of 45 · 885 trades